Post by CureVac

CureVac is advancing the science of #mRNA medicines through five exciting presentations at the 13th International mRNA Conference in Berlin and online. Join us on November 11 & 12, 2025, as our researchers share new insights into next-generation mRNA technologies. Don’t miss our featured talk on November 11 by Sandro Roier, Senior Scientist Infectious Diseases: “An mRNA-Based FimH Nanoparticle Vaccine Against Uropathogenic E. Coli Confers Protection in a Mouse Model of Recurrent Urinary Tract Infection” (02:54–03:10 pm), showcasing progress toward tackling complex bacterial infections. We’ll also present posters on November 11 on:  🔵 Development of a Proprietary LNP Platform with Optimized Biodistribution and Immunogenicity for Multiepitope mRNA-Based Cancer Immunotherapy: Presented by Katharina Wolter, Scientist Oncology  🔵 Immune Stimulating Properties of LNP Formulations Containing a PEG Alternative: Presented by Dr. Christine Rueckert , Associate Director MATech  🔵 Optimizing mRNA Therapeutics: Focus on Sequence Parameters and RNA Chemistry: Presented by Moritz Thran, Senior Scientist Enabling Technologies   and on November 12 on:   🔵 Thermostable Single-Dose LNP Platform for Prophylactic mRNA Vaccines: Presented by Roland Böttger, Senior Scientist Formulation These studies reflect CureVac’s continued commitment to translating mRNA science into real-world health solutions. Explore our sessions and learn more about CureVac’s contributions to mRNA innovation here: https://lnkd.in/e68C8Tq8 #immunotherapy #oncology #mRNAhealthconference #mRNA2025

Video Content